CD13、CD33在BCR-ABL+急性淋巴细胞白血病患者骨髓中的表达及其与临床特征和预后的相关性

目的:探讨髓系抗原CD13、CD33在BCR-ABL+急性淋巴细胞白血病（acute lymphoblastic leukemia，ALL）患者骨髓中的表达及其与临床特征和预后的相关性。方法:应用实时荧光定量聚合酶链反应（real time quantitative-polymerase chain reaction,RQ-PCR）检测119例初诊ALL患者骨髓BCR-ABL表达水平。用流式细胞学检查检测ALL的抗原表达水平。对照分析单纯BCR-ABL+患者中CD13+和CD13-以及CD33+和CD33-患者在初次诱导缓解率（initial-induction remission rate，CR1）和总生存率（overall survival rate，OS）的区别。结果:在BCR-ABL+ 的ALL患者中，初诊时CD13+患者较CD13-患者具有较低的首次诱导缓解率，差异具统计学意义（P＜0.05），但CD33+患者较CD33-患者首次诱导缓解率无统计学差异。CD13+组及CD33+的OS显著低于CD13-组及CD33-组（P＜0.05）。结论:BCR-ABL+ALL患者中CD13+及CD33+提示预后不良。

Expression of CD13 and CD33 in bone marrow of patients with BCR-ABL+ acute lymphoblastic leukemia and their correlation with clinical features and prognosis

Objective:To investigate the expression of myeloid antigens CD13 and CD33 in bone marrow of patients with BCR-ABL+ acute lymphoblastic leukemia and their correlation with clinical features and prognosis.Methods:RQ-PCR was used to detect the expression level of BCR-ABL in bone marrow of 119 patients with newly diagnosed ALL，and the expression level of ALL antigen was detected by flow cytometry.The difference between CD13+ and CD13- and CD33+ and CD33- patients in CR1 and OS was analyzed.Results:In ALL patients with BCR-ABL+，CD13+ patients had a lower initial-induction remission rate than CD13- patients at initial diagnosis，and the difference was statistically significant(P＜0.05)，but there was no significant difference in the initial-induction remission rate between CD33+ patients and CD33- patients.The OS of CD13+ and CD33+ groups were significantly lower than that of CD13- and CD33- groups(P＜0.05).Conclusion:CD13+ and CD33+ in BCR-ABL+ ALL patients indicate poor prognosis.